Emma Rybalka

1.7k total citations
48 papers, 1.2k citations indexed

About

Emma Rybalka is a scholar working on Molecular Biology, Physiology and Rehabilitation. According to data from OpenAlex, Emma Rybalka has authored 48 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 18 papers in Physiology and 12 papers in Rehabilitation. Recurrent topics in Emma Rybalka's work include Muscle Physiology and Disorders (23 papers), Exercise and Physiological Responses (12 papers) and Adipose Tissue and Metabolism (8 papers). Emma Rybalka is often cited by papers focused on Muscle Physiology and Disorders (23 papers), Exercise and Physiological Responses (12 papers) and Adipose Tissue and Metabolism (8 papers). Emma Rybalka collaborates with scholars based in Australia, Switzerland and United States. Emma Rybalka's co-authors include Cara A. Timpani, Alan Hayes, Matthew B. Cooke, Nuri Gueven, Dean G. Campelj, Andrew D. Williams, Kulmira Nurgali, Paul J. Cribb, Craig A. Goodman and Dirk Fischer and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Emma Rybalka

47 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emma Rybalka Australia 20 718 378 229 214 131 48 1.2k
Alex Shimura Yamashita Brazil 24 610 0.8× 551 1.5× 347 1.5× 133 0.6× 114 0.9× 31 1.5k
Kechun Tang United States 20 707 1.0× 342 0.9× 150 0.7× 123 0.6× 75 0.6× 36 1.4k
Sven W. Görgens Germany 14 448 0.6× 575 1.5× 255 1.1× 141 0.7× 98 0.7× 19 1.1k
Bumsoo Ahn United States 20 729 1.0× 560 1.5× 247 1.1× 163 0.8× 31 0.2× 42 1.2k
Birgitte Ursø Denmark 20 769 1.1× 342 0.9× 103 0.4× 409 1.9× 101 0.8× 25 1.6k
Jennifer S. Moylan United States 19 1.3k 1.8× 799 2.1× 474 2.1× 279 1.3× 144 1.1× 29 2.1k
Johanna Ábrigo Chile 21 593 0.8× 522 1.4× 129 0.6× 221 1.0× 51 0.4× 29 1.1k
Janne R. Hingst Denmark 15 949 1.3× 682 1.8× 172 0.8× 281 1.3× 30 0.2× 27 1.5k
Nasser Al‐Shanti United Kingdom 19 563 0.8× 345 0.9× 142 0.6× 139 0.6× 52 0.4× 38 926
Scott K. Powers United States 16 628 0.9× 476 1.3× 343 1.5× 287 1.3× 28 0.2× 21 1.4k

Countries citing papers authored by Emma Rybalka

Since Specialization
Citations

This map shows the geographic impact of Emma Rybalka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Rybalka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Rybalka more than expected).

Fields of papers citing papers by Emma Rybalka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Rybalka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Rybalka. The network helps show where Emma Rybalka may publish in the future.

Co-authorship network of co-authors of Emma Rybalka

This figure shows the co-authorship network connecting the top 25 collaborators of Emma Rybalka. A scholar is included among the top collaborators of Emma Rybalka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Rybalka. Emma Rybalka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Timpani, Cara A., Xu Yan, Jujiao Kuang, et al.. (2025). Repurposed Nrf2 activator dimethyl fumarate rescues muscle inflammation and fibrosis in an aggravated mdx mouse model of Duchenne muscular dystrophy. Redox Biology. 84. 103676–103676. 1 indexed citations
2.
Timpani, Cara A., Dean G. Campelj, Narges Dargahi, et al.. (2023). Dimethyl fumarate modulates the dystrophic disease program following short-term treatment. JCI Insight. 8(21). 6 indexed citations
3.
Timpani, Cara A., Craig A. Goodman, Christos G. Stathis, et al.. (2020). Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy. Scientific Reports. 10(1). 1125–1125. 27 indexed citations
4.
Gueven, Nuri, et al.. (2020). Idebenone: When an antioxidant is not an antioxidant. Redox Biology. 38. 101812–101812. 70 indexed citations
5.
Timpani, Cara A., et al.. (2020). Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?. Pharmaceuticals. 13(10). 306–306. 63 indexed citations
6.
Campelj, Dean G., Cara A. Timpani, Aaron C. Petersen, et al.. (2020). The Paradoxical Effect of PARP Inhibitor BGP-15 on Irinotecan-Induced Cachexia and Skeletal Muscle Dysfunction. Cancers. 12(12). 3810–3810. 12 indexed citations
7.
Timpani, Cara A., et al.. (2020). Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy. Redox Biology. 38. 101803–101803. 36 indexed citations
8.
McQuade, Rachel M., Aaron C. Petersen, Raquel Abalo, et al.. (2019). Co-treatment With BGP-15 Exacerbates 5-Fluorouracil-Induced Gastrointestinal Dysfunction. Frontiers in Neuroscience. 13. 449–449. 8 indexed citations
9.
Cooke, Matthew B., Emma Rybalka, Christos G. Stathis, & Alan Hayes. (2018). Myoprotective Potential of Creatine Is Greater than Whey Protein after Chemically-Induced Damage in Rat Skeletal Muscle. Nutrients. 10(5). 553–553. 4 indexed citations
10.
Qaradakhi, Tawar, Minos–Timotheos Matsoukas, Alan Hayes, et al.. (2017). Alamandine reverses hyperhomocysteinemia-induced vasculardysfunction via PKA-dependent mechanisms. Cardiovascular Therapeutics. 3 indexed citations
11.
12.
McQuade, Rachel M., Vanesa Stojanovska, Ahmed A. Rahman, et al.. (2017). Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons. Frontiers in Physiology. 8. 391–391. 25 indexed citations
13.
Petersen, Aaron C., Cara A. Timpani, Dean G. Campelj, et al.. (2017). BGP-15 Protects against Oxaliplatin-Induced Skeletal Myopathy and Mitochondrial Reactive Oxygen Species Production in Mice. Frontiers in Pharmacology. 8. 137–137. 37 indexed citations
14.
Timpani, Cara A., Alan Hayes, & Emma Rybalka. (2017). Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy. Orphanet Journal of Rare Diseases. 12(1). 100–100. 18 indexed citations
15.
Timpani, Cara A., et al.. (2016). Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?. Cancer Chemotherapy and Pharmacology. 78(4). 673–683. 67 indexed citations
16.
Qaradakhi, Tawar, Alan Hayes, Emma Rybalka, et al.. (2016). IRAP inhibition using HFI419 prevents moderate to severe acetylcholine mediated vasoconstriction in a rabbit model. Biomedicine & Pharmacotherapy. 86. 23–26. 8 indexed citations
17.
Timpani, Cara A., et al.. (2015). Idebenone protects against chemotherapy-induced skeletal muscle wasting and mitochondrial dysfunction in mice. Victoria University Research Repository (Victoria University). 1 indexed citations
18.
Timpani, Cara A., Alan Hayes, & Emma Rybalka. (2015). Revisiting the dystrophin-ATP connection: How half a century of research still implicates mitochondrial dysfunction in Duchenne Muscular Dystrophy aetiology. Medical Hypotheses. 85(6). 1021–1033. 100 indexed citations
19.
20.
Rybalka, Emma, et al.. (2014). Skeletal muscle atrophy in sedentary Zucker obese rats is not caused by calpain-mediated muscle damage or lipid peroxidation induced by oxidative stress. Journal of Negative Results in BioMedicine. 13(1). 19–19. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alex Shimura Yamashita Breakdown of academic impact, for papers by Kechun Tang Breakdown of academic impact, for papers by Sven W. Görgens Breakdown of academic impact, for papers by Bumsoo Ahn Breakdown of academic impact, for papers by Birgitte Ursø Breakdown of academic impact, for papers by Jennifer S. Moylan Breakdown of academic impact, for papers by Johanna Ábrigo Breakdown of academic impact, for papers by Janne R. Hingst Breakdown of academic impact, for papers by Nasser Al‐Shanti Breakdown of academic impact, for papers by Scott K. Powers
Rankless by CCL
2026